Safe Anastomosis Feasibility Study

Colorectal Cancer Clinical Trial

— SAFE2019  

Official title:

Safe Anastomosis Feasibility Study: a Study to Investigate the Efficacy, Mechanism of Action and Safety of the Colovac+ Colorectal Anastomosis Protection Device

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05180565
• Other study ID #: SAFE2019
• Status: Completed
• Phase: N/A
• Start date: December 18, 2019
• Est. completion date: March 31, 2022

Study information

• Verified date: May 2022
• Source: SafeHeal Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A clinical trial to assess the efficacy, mechanism of action and safety of the Colovac+ Colorectal Anastomosis Protection Device in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer

Description:

A primary diverting stoma is widely used by surgeons in order to bypass the low rectal anastomosis and reduce morbidity associated with anastomotic leaks. Typically, a stoma is created for all high-risk patients which means that many patients are exposed to potentially serious complications associated with the stoma itself without any clinical benefit.

Colovac+ is a local, temporary, minimally invasive bypass device that provides protection of the anastomosis and safely postpones stoma creation for 10 days after surgery. By postponing stoma creation for 10 days, Colovac is designed to avoid stoma creation in all patients except those patients whose anastomoses have not healed by 10 days after surgery, allowing the others to return to normal activity more quickly and safely.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: March 31, 2022
• Est. primary completion date: February 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (18 years of age or older)

• Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for malignancy, based on multidisciplinary team recommendations.

• Willingness to comply with Clinical Investigation Plan-specific treatment and study visits and to sign a written Informed Consent Form

Exclusion Criteria:

• Preoperatively :

1. Patient with inflammatory bowel disease

2. Known allergy to nickel or other components of the Colovac+ kit

3. Pregnant or nursing female subject

4. Concomitant major surgical procedure in combination with Colorectal resection (i.e. hepatectomy)

5. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo Clinical Investigation Plan described procedures or interfere with the interpretation of study results. including, but not limited to:

1. COVID-19 positive (active infection) based on test within 72 hours prior to surgery

2. Metastatic disease - unless previously treated with chemotherapy and resection, and the benefit of exposure to the Colovac device is greater than the risk 1

3. Immunodeficiency (CD4+ count < 500 CU MM)

4. Systemic steroid therapy within the past 6 months

5. Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery

6. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study

7. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis

8. Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging

9. Severe Malnutrition defined as 10% weight loss within 3 months prior to enrollment.

6. The subject is currently participating in another investigational drug or device study

• Intraoperatively :

7. Anastomosis placement at more than 10cm from anal margin

8. Occurrence of any of the following during the colorectal surgery:

1. Blood loss (>750 cc)

2. Blood transfusion

3. Any new sign of ischemia

4. Positive air leak test - requiring re intervention on the anastomosis

5. Inadequate bowel preparation

6. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device

Related Conditions & MeSH terms

• Anastomosis
• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Device:
• Colovac
A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)

Locations

Country	Name	City	State
Belgium	UZA	Antwerp
Belgium	Centre Hospitalier Universitaire St Pierre	Brussels
France	CHU Lille	Lille
France	ICM Montpellier	Montpellier
France	Hôpital Saint Antoine Paris	Paris
France	Hôpital Saint Louis	Paris
France	CHRU Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
SafeHeal Inc

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To measure the incidence of serious adverse events related to using the device	The primary endpoint will be a measurement of SAEs probably related or causaly related to the use of the investigational device, to the index surgery in this clinical trial.	3 months
Secondary	To measure the number of participants with evidence of absence of feces between the sheath and the colonic wall before device retrieval	Rate of patients with evidence of absence of feces between the sheath and the colonic wall before device retrieval at 10 days:	10 days
Secondary	To measure the rate of ostomy avoidance	To measure the number of participants where ostomy was avoided	3 months
Secondary	To evaluate the occurrence of clinical anastomotic leakage		3 months
Secondary	To measure on a scale of 1 to 5 rated by the surgeon the ease of device introduction, positioning and endoscopic retrieval	Ease of device introduction and positioning will be rated by the surgeon on a scale from 1 to 5 (1 being very easy and 5 being impossible); Ease of endoscopic retrieval of the device will be rated by the endoscopist on a scale from 1 to 5 (1 being very easy and 5 being impossible)	10 days
Secondary	To evaluate the clinically significant migration rate		10 days
Secondary	To evaluate the integrity above the anchoring site during the device retrieval using endoscopy.	Mucosal appearance above the anchoring site will be evaluated endoscopically during device retrieval and classified as Normal/Inflamed, Bleeding, Ulcerated, Perforated.	10 days
Secondary	To evaluate the integrity of the anchoring site during the device retrieval using endoscopy.	Mucosal appearance at the anchoring site will be evaluated endoscopically during device retrieval and classified as Normal/Inflamed, Bleeding, Ulcerated, Perforated.	10 days
Secondary	To evaluate the integrity of the anastomosis before the device retrieval using fluoroscopy	Fluoroscopy with injection of contrast between the colonic wall and the sheath will be performed prior to retrieval of the Colovac+ Device in order to check for anastomotic integrity before device retrieval.; Outcome is measured with presence/absence of any contrast liquid leak through the anastomosis prior to device retrieval.	10 days
Secondary	To evaluate the integrity of the anastomosis after the device retrieval using fluoroscopy	Fluoroscopy with injection of contrast per rectum will be performed immediately after retrieval of the Colovac+ Device in order to check for anastomotic integrity following device retrieval.; Outcome is measured with presence/absence of any contrast liquid leak through the anastomosis after device retrieval.	10 days
Secondary	To measure the average procedure time		1 day
Secondary	To measure the patient tolerability of the device using a patient questionnaire	Responses to a patient questionnaire on device acceptance, on the device handling and comfort, and on preference compared to an ostomy - utilizing the NIH's (National Institute of Health) PROMIS (Patient-Reported Outcomes Measurement Information System) health measurement questionnaires to assess parameters like pain, bowel incontinence, constipation, diarrhea, or anxiety and social isolation, on a scale from 1 to 10 (1 being absence of difficulty and 10 being severe problems).	10 days